Pharmacological activity itself does not necessarily result in a clinically relevant benefit.

Drugs from the Schwabe laboratories are therefore tested in randomized, controlled, double-blind clinical trials to assess clinical efficacy and safety in human use. These trials are performed in the same way as it is done for synthetical drugs.
The clinical studies are performed by the clinical research unit in accordance with the ICH-GCP guidelines.

Sophisticated statistical analyses provide objective assessments of the results and, where appropriate, also assess quality of life and overall therapeutic benefits with regard to pharmacoeconomic and social politics issues.

Schwabe's clinical research on phytopharmaceuticals derived from plants such as Ginkgo biloba, Saw Palmetto, Hawthorn, and St. John's Wort has significantly contributed to the acceptance of evidence-based phytotherapy in the medical community.

The results of these clinical investigations are published in internationally recognised scientific journals and are the basis for more than 800 drug registrations Schwabe has achieved world-wide.